Biocon is currently trading at RS. 366.70, up by 2.75 points or 0.76% from its previous closing of RS. 363.95 on the BSE.

The stock opened at RS. 364.20 and touched a high of RS. 369.00 and a low of RS. 364.20. A total of 8331 shares have been traded so far.

The BSE group 'A' stock with a face value of RS. 5 has recorded a 52-week high of RS. 405.90 on July 18, 2025, and a 52-week low of RS. 290.80 on March 3, 2025. Over the last week, the scrip’s high and low stood at RS. 370.75 and RS. 353.15, respectively. The company’s current market capitalization is RS. 49313.90 crore.

Promoter holding in the company stands at 54.45%, while Institutions and Non-Institutions hold 28.86% and 16.68% respectively.

In a major development, Biocon has inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly-owned subsidiary, Biocon Generics Inc (BGI). The company had acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and invested over $30 million to upgrade it into a state-of-the-art plant with an annual production capacity of 2 billion tablets. Several products have already been commercialized, with more in the pipeline.

This strategic investment enables Biocon to diversify its manufacturing base, strengthen its supply chain, and expand its global footprint. The Cranbury facility will help improve access to essential therapies, enhance supply reliability, and reinforce Biocon’s partnerships with healthcare providers in the U.S., ultimately benefitting patients.

Biocon is India’s largest and Asia’s leading biotechnology company, focused on biopharmaceuticals and research services. It is an innovation-driven enterprise offering affordable solutions for chronic diseases to patients worldwide.